Canaccord Genuity Group Cuts Biogen (NASDAQ:BIIB) Price Target to $220.00
Biogen (NASDAQ:BIIB – Free Report) had its target price cut by Canaccord Genuity Group from $265.00 to $220.00 in a research report sent to investors on Friday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. Several other research analysts have also commented on the stock. Royal Bank of Canada lifted their […]
Biogen (NASDAQ:BIIB – Free Report) had its target price cut by Canaccord Genuity Group from $265.00 to $220.00 in a research report sent to investors on Friday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. Several other research analysts have also commented on the stock. Royal Bank of Canada lifted their […]
